巴西批准在2026年推出首种单剂量登革热疫苗,该疫苗对严重病例有效。 Brazil approves first single-dose dengue vaccine, effective against severe cases, for rollout in 2026.

巴西已批准由圣保罗的布坦坦研究所为12至59岁人口开发的世界上第一种单剂量登革热疫苗Butantan-DV。 Brazil has approved the world’s first single-dose dengue vaccine, Butantan-DV, for people aged 12 to 59, developed by the Butantan Institute in São Paulo. 在有16 000多名参与者的试验中,疫苗显示91.6%对严重登革热的疗效,预计将在2026年初推广。 The vaccine showed 91.6% efficacy against severe dengue in trials with over 16,000 participants and is expected to be rolled out in early 2026. 与现有的两用剂量选择相比,它简化了疫苗接种。 It simplifies vaccination compared to existing two-dose options. 2024年,全球登革热病例激增,感染人数超过1 460万,死亡近12 000人,其中一半在巴西,其部分原因是气候变化扩大了蚊虫栖息地。 Dengue cases surged globally in 2024, with over 14.6 million infections and nearly 12,000 deaths, half in Brazil, driven in part by climate change expanding mosquito habitats. 巴西计划在WuXi生物学的帮助下,到2026年年中生产3 000万剂。 Brazil plans to produce 30 million doses by mid-2026 with help from WuXi Biologics.